Clinical trial
Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic…
NCT00277758 · Weill Medical College of Cornell University, Other · Terminated
Key facts
| NCT number | NCT00277758 |
|---|---|
| Title | Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I |
| Official title | A Phase I Study of Low Dose Interleukin 2 (IL-2)Monotherapy, Followed by IL-2 Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I Infection |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Biological, Drug |
| Interventions | Interleukin 2, Ribavirin, Pegylated Interferon Alpha, Inteleukin-2, Ribavirin + Pegylated interferon-alpha |
| Enrollment | 18 |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Jan 16, 2006 |
| Last update posted | Mar 7, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: